Research across Non-Hodgkin's Lymphoma
Related studies from across the Non-Hodgkin's Lymphoma family.
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma
Trial Shows Brexucabtagene Autoleucel Provides Durable Benefit for Blood Cancers
This meta-analysis of 31 cohorts evaluates brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma and B-cell acute lympho…
Brexucabtagene autoleucel shows high response rates and durable benefits for adults with specific types of relapsed or refractory blood canc…
Allo-HSCT after CAR-T yields sustained remission in DLBCL patient with secondary MDS
CAR-T and transplant may lead to secondary leukemia
This case report and literature review describes a single patient with primary splenic DLBCL who developed secondary myelodysplastic syndrom…
A patient developed a secondary blood cancer after CAR-T therapy and transplant, but a later transplant brought remission.
Multifaceted preventive nursing program reduces fall incidence from 19.8% to 7.1% in elderly NHL patients
Nursing Program Reduces Fall Risk for Lymphoma Patients
This randomized controlled trial of 210 older adults with non-Hodgkin's lymphoma found that a multifaceted preventive nursing program signif…
A specialized nursing program significantly reduced falls and improved mobility for older adults undergoing chemotherapy for lymphoma.
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.